BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 27181776)

  • 1. Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Langman CB; Barshop BA; Deschênes G; Emma F; Goodyer P; Lipkin G; Midgley JP; Ottolenghi C; Servais A; Soliman NA; Thoene JG; Levtchenko EN;
    Kidney Int; 2016 Jun; 89(6):1192-203. PubMed ID: 27181776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of long-term cysteamine treatment in patients with cystinosis.
    Ariceta G; Giordano V; Santos F
    Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
    Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
    Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
    Nesterova G; Williams C; Bernardini I; Gahl WA
    Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrarenal complications of cystinosis.
    Topaloglu R
    Pediatr Nephrol; 2024 Aug; 39(8):2283-2292. PubMed ID: 38127152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTNS mRNA molecular analysis revealed a novel mutation in a child with infantile nephropathic cystinosis: a case report.
    Papizh S; Serzhanova V; Filatova A; Skoblov M; Tabakov V; van den Heuvel L; Levtchenko E; Prikhodina L
    BMC Nephrol; 2019 Oct; 20(1):400. PubMed ID: 31672123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephropathic cystinosis: an update on genetic conditioning.
    Topaloglu R
    Pediatr Nephrol; 2021 Jun; 36(6):1347-1352. PubMed ID: 32564281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephropathic Cystinosis Mimicking Bartter Syndrome: a Novel Mutation.
    Bastug F; Nalcacioglu H; Ozaltin F; Korkmaz E; Yel S
    Iran J Kidney Dis; 2018 Jan; 12(1):61-63. PubMed ID: 29421779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cystinosis in adults: A systemic disease].
    Servais A; Goizet C; Bertholet-Thomas A; Decramer S; Llanas B; Choukroun G; Novo R
    Nephrol Ther; 2015 Jun; 11(3):152-9. PubMed ID: 25769364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystinosis: a review.
    Elmonem MA; Veys KR; Soliman NA; van Dyck M; van den Heuvel LP; Levtchenko E
    Orphanet J Rare Dis; 2016 Apr; 11():47. PubMed ID: 27102039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.
    Brodin-Sartorius A; Tête MJ; Niaudet P; Antignac C; Guest G; Ottolenghi C; Charbit M; Moyse D; Legendre C; Lesavre P; Cochat P; Servais A
    Kidney Int; 2012 Jan; 81(2):179-89. PubMed ID: 21900880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystinosis: clinical presentation, pathogenesis and treatment.
    Ivanova E; De Leo MG; De Matteis MA; Levtchenko E
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():176-84. PubMed ID: 25345100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cystinosis: From the gene identification to the first gene therapy clinical trial].
    Cherqui S
    Med Sci (Paris); 2023 Mar; 39(3):253-261. PubMed ID: 36943122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathogenesis of cystinosis: mechanisms beyond cystine accumulation.
    Wilmer MJ; Emma F; Levtchenko EN
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F905-16. PubMed ID: 20826575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follow-up and treatment of adults with cystinosis in the Netherlands.
    Geelen JM; Monnens LA; Levtchenko EN
    Nephrol Dial Transplant; 2002 Oct; 17(10):1766-70. PubMed ID: 12270982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystinosin-deficient rats recapitulate the phenotype of nephropathic cystinosis.
    Hollywood JA; Kallingappa PK; Cheung PY; Martis RM; Sreebhavan S; 'Atiola RD; Chatterjee A; Buckels EJ; Matthews BG; Lewis PM; Davidson AJ
    Am J Physiol Renal Physiol; 2022 Aug; 323(2):F156-F170. PubMed ID: 35695380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis.
    Emma F; Hoff WV; Hohenfellner K; Topaloglu R; Greco M; Ariceta G; Bettini C; Bockenhauer D; Veys K; Pape L; Hulton S; Collin S; Ozaltin F; Servais A; Deschênes G; Novo R; Bertholet-Thomas A; Oh J; Cornelissen E; Janssen M; Haffner D; Ravà L; Antignac C; Devuyst O; Niaudet P; Levtchenko E
    Kidney Int; 2021 Nov; 100(5):1112-1123. PubMed ID: 34237326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
    Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
    Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.
    Hollywood JA; Przepiorski A; D'Souza RF; Sreebhavan S; Wolvetang EJ; Harrison PT; Davidson AJ; Holm TM
    J Am Soc Nephrol; 2020 May; 31(5):962-982. PubMed ID: 32198276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic Stem Cell Gene Therapy for Cystinosis: From Bench-to-Bedside.
    Cherqui S
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.